Actinium-225 Prostate-specific Membrane Antigen Theranostics: Will alpha Beat beta?
Details
Publication Year 2021-03,Volume 79,Issue #3,Page 351-352
Journal Title
European Urology
Publication Type
Commentary
Abstract
Optimisation of prostate-specific membrane antigen (PSMA) based radioligand therapy (RLT) requires a focus on prospective trials.
Keywords
Actinium; Humans; Male; *Precision Medicine; Prospective Studies; *Prostate
Department(s)
Cancer Imaging
PubMed ID
33436167
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2026-01-30 05:59:56
Last Modified: 2026-01-30 06:01:39
An error has occurred. This application may no longer respond until reloaded. Reload 🗙